1. P1115: A MULTICENTER PHASE 1/2 TRIAL OF EO2463, A MICROBIAL-DERIVED PEPTIDE THERAPEUTIC VACCINE, AS MONOTHERAPY AND IN COMBINATION WITH LENALIDOMIDE AND RITUXIMAB, FOR TREATMENT OF PATIENTS WITH INDOLENT NHL. (23rd June 2022) Authors: Zinzani, P. L.; Ansell, S. M.; Bosch, F.; Friedberg, J. W.; Marolleau, J. P.; Arcaini, L.; Garcia-Sanz, R.; Gopal, A. K.; Grande, C.; Merryman, R.; Pinto, A.; Smith, S. D.; Villasboas, J. C.; Wallace, D.; Fagerberg, J.; Magalhaes, J. G.; Armand, P. Journal: HemaSphere Issue: Volume 6(2022)Supplement 3 Page Start: 1005 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗